These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 26968418)
1. Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Velaer KN; Steinberg RL; Thomas LJ; O'Donnell MA; Nepple KG Curr Urol Rep; 2016 May; 17(5):38. PubMed ID: 26968418 [TBL] [Abstract][Full Text] [Related]
2. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482 [TBL] [Abstract][Full Text] [Related]
3. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066 [TBL] [Abstract][Full Text] [Related]
4. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy. Haas CR; McKiernan JM Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299 [TBL] [Abstract][Full Text] [Related]
5. Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer. Abou Chakra M; McElree IM; Packiam VT; Mott SL; O'Donnell MA Urol Oncol; 2024 Sep; 42(9):289.e13-289.e21. PubMed ID: 38796357 [TBL] [Abstract][Full Text] [Related]
6. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400 [TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506 [TBL] [Abstract][Full Text] [Related]
11. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502 [TBL] [Abstract][Full Text] [Related]
12. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101 [TBL] [Abstract][Full Text] [Related]
13. Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Barlow LJ; Benson MC Curr Urol Rep; 2013 Apr; 14(2):65-70. PubMed ID: 23378162 [TBL] [Abstract][Full Text] [Related]
14. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols. Ben-David R; Tillu N; Alerasool P; Bieber C; Ranti D; Tolani S; Eisenhauer J; Chung R; Lavallée E; Waingankar N; Attalla K; Wiklund P; Mehrazin R; Anderson CB; Sfakianos JP World J Urol; 2024 May; 42(1):315. PubMed ID: 38734774 [TBL] [Abstract][Full Text] [Related]
15. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Yim K; Melnick K; Mott SL; Carvalho FLF; Zafar A; Clinton TN; Mossanen M; Steele GS; Hirsch M; Rizzo N; Wu CL; Mouw KW; Wszolek M; Salari K; Feldman A; Kibel AS; O'Donnell MA; Preston MA Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933 [TBL] [Abstract][Full Text] [Related]
16. Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Pareek T; Parmar K; Sharma AP; Kumar S Urol Int; 2022; 106(8):784-790. PubMed ID: 35654025 [TBL] [Abstract][Full Text] [Related]
17. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275 [TBL] [Abstract][Full Text] [Related]